These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 1471868)

  • 1. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease.
    Baronti F; Mouradian MM; Davis TL; Giuffra M; Brughitta G; Conant KE; Chase TN
    Ann Neurol; 1992 Dec; 32(6):776-81. PubMed ID: 1471868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease.
    Mouradian MM; Heuser IJ; Baronti F; Chase TN
    Ann Neurol; 1990 Jan; 27(1):18-23. PubMed ID: 2301923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease.
    Vaamonde J; Luquin MR; Obeso JA
    Mov Disord; 1990; 5(3):260-2. PubMed ID: 2388647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Changes in the nigrostriatal dopamine receptor compartment after continuous dopaminergic infusions in Parkinson disease].
    Baronti F; Ruggieri S; Mouradian MM; Bonamartini A; Bocciarelli P; De Pandis MF; Chase TN; Agnoli A
    Riv Neurol; 1991; 61(6):210-4. PubMed ID: 1813972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.
    Bravi D; Mouradian MM; Roberts JW; Davis TL; Sohn YH; Chase TN
    Ann Neurol; 1994 Jul; 36(1):27-31. PubMed ID: 8024257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic s.c. lisuride in Parkinson's disease--motor-performance and avoidance of psychiatric side effects.
    Bittkau S; Przuntek H
    J Neural Transm Suppl; 1988; 27():35-54. PubMed ID: 3165438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous lisuride corrects oscillations of motor performance in Parkinson's disease.
    Obeso JA; Luquin MR; Martínez Lage JM
    Ann Neurol; 1986 Jan; 19(1):31-5. PubMed ID: 3947037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Lisuride in the combination treatment of Parkinson disease].
    Jellinger K
    Wien Med Wochenschr; 1987 Apr; 137(7-8):155-9. PubMed ID: 3111099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease.
    Chase TN; Engber TM; Mouradian MM
    Neurology; 1994 Jul; 44(7 Suppl 6):S15-8. PubMed ID: 7519334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.
    Mouradian MM; Juncos JL; Fabbrini G; Schlegel J; Bartko JJ; Chase TN
    Ann Neurol; 1988 Sep; 24(3):372-8. PubMed ID: 3228271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The dopamine agonist, lisuride, in the therapy of Parkinson disease].
    Madeja UD
    Acta Histochem Suppl; 1992; 42():25-31. PubMed ID: 1584973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [On-off phenomena in Parkinson's disease. Continuous dopaminergic stimulation].
    Stocchi F; Ruggieri S; Baronti F; Bellantuono P; Brughita G; Antonini A; Bravi D; Agnoli A
    Clin Ter; 1987 Jul; 122(2):83-8. PubMed ID: 2973904
    [No Abstract]   [Full Text] [Related]  

  • 13. Can we differentiate symptomatic and neuroprotective effects in parkinsonism? The dopamine agonist lisuride delays the need for levodopa therapy to a similar extent as reported for deprenyl.
    Runge I; Horowski R
    J Neural Transm Park Dis Dement Sect; 1991; 3(4):273-83. PubMed ID: 1772580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of sustained dopaminergic stimulation.
    Stocchi F; Patsalos PN; Berardelli A; Barbato L; Bonamartini A; Manfredi M; Ruggieri S
    Clin Neuropharmacol; 1994; 17 Suppl 2():S7-13. PubMed ID: 9358190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease.
    Stocchi F; Ruggieri S; Vacca L; Olanow CW
    Brain; 2002 Sep; 125(Pt 9):2058-66. PubMed ID: 12183351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Problems in daily motor performances in Parkinson's disease: the continuous dopaminergic stimulation.
    Stocchi F; Ruggieri S; Brughitta G; Agnoli A
    J Neural Transm Suppl; 1986; 22():209-18. PubMed ID: 3465872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors.
    Olanow CW; Obeso JA
    Neurology; 2000; 55(11 Suppl 4):S72-7; discussion S78-81. PubMed ID: 11147513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between L-dopa and lisuride intravenous infusions: a clinical study.
    Ruggieri S; Stocchi F; Carta A; Bravi D; Bragoni M; Giorgi L; Agnoli A
    Mov Disord; 1988; 3(4):313-9. PubMed ID: 3211176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980.
    Bravi D; Davis TL; Mouradian MM; Chase TN
    Mov Disord; 1993 Apr; 8(2):195-7. PubMed ID: 8097280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous lisuride infusion in Parkinson's disease: clinical results using different modes of administration.
    Stocchi F; Ruggieri S; Antonini A; Baronti F; Brughitta G; Bellantuono P; Bravi D; Agnoli A
    J Neural Transm Suppl; 1988; 27():27-33. PubMed ID: 3165437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.